Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShire Regulatory News (SHP)

  • There is currently no data for SHP

Form 8.5 (EPT/RI) - SHIRE PLC

11 Dec 2018 11:08

RNS Number : 1164K
Morgan Stanley & Co. LLC
11 December 2018
Β 

Β 

Β FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

Β 

1. KEY INFORMATION

Β 

(a) Name of exempt principal trader:

Morgan Stanley & Co. LLC

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Shire plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Β 

Shire plc

(d) Date dealing undertaken:

10 DECEMBER 2018

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

Yes - Takeda Pharmaceutical Company Limited

Β 

Β 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Β 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

Β 

Β The currency of all prices and other monetary amounts should be stated.

Β 

Β 

(a) Purchases and sales

Β 

Β Class of relevant security

Β Purchases/sales

Β Total number of securities

Β Highest price per unit paid/received

Β Lowest price per unit paid/received

Β ADR

Β PURCHASES

Β 541,760

Β 171.3600 USD

Β 168.6600 USD

Β ADR

Β SALES

Β 548,850

Β 171.3600 USD

Β 168.6600 USD

Β 5p ordinary

Β PURCHASES

Β 45,709

Β 45.0650 GBP

Β 44.9934 GBP

Β 5p ordinary

Β SALES

Β 45,709

Β 45.0617 GBP

Β 44.9926 GBP

Β 

Β 

(b) Cash-settled derivative transactions

Β 

Β Class of relevant security

Β Product description

e.g. CFD

Β Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Β Number of reference securities

Β Price per unit

Β N/A

Β N/A

Β N/A

Β N/A

Β N/A

Β 

Β 

(c) Stock-settled derivative transactions (including options)

Β 

(i) Writing, selling, purchasing or varying

Β 

Β Class of relevant security

Β Product description e.g. call option

Β Writing, purchasing, selling, varying etc.

Β Number of securities to which option relates

Β Exercise price per unit

Β Type e.g. American, European etc.

Β Expiry date

Β Option money paid/ received per unit

Β ADR

Β PUT

Β SALE

Β 100

Β 170.0000

Β A

Β 14/12/2018

Β 1.6900 USD

Β 

(ii) Exercise

Β 

Β Class of relevant security

Β Product description e.g. call option

Β Number of securities

Β Exercise price per unit

Β N/A

Β N/A

Β N/A

Β N/A

Β 

(d) Other dealings (including subscribing for new securities)

Β 

Β Class of relevant security

Β Nature of dealing e.g. subscription, conversion

Β Details

Β Price per unit (if applicable)

Β N/A

Β N/A

Β N/A

Β N/A

Β 

The currency of all prices and other monetary amounts should be stated.

Β 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

Β 

Β 

Β 

3. OTHER INFORMATION

Β 

(a) Indemnity and other dealing arrangements

Β 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

Β 

None

Β 

Β 

Β 

Β 

(b) Agreements, arrangements or understandings relating to options or derivatives

Β 

Β 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

Β 

None

Β 

Β 

Β 

Β 

Date of disclosure:

11 DECEMBER 2018

Contact name:

Craig Horsley

Telephone number:

+44(141) 245 7736

Β 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

Β 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
FEREAFAFFEKPFFF
Date   Source Headline
4th Dec 201810:46 amRNSForm 8.5 (EPT/RI) - SHIRE PLC
4th Dec 201810:45 amRNSForm 8.5 (EPT/RI) - SHIRE PLC
4th Dec 201810:44 amRNSForm 8.5 (EPT/RI) - SHIRE PLC
4th Dec 201810:42 amRNSForm 8.5 (EPT/RI)
4th Dec 201810:34 amRNSForm 8.5 (EPT/RI)- Shire plc
4th Dec 201810:31 amRNSForm 8.5 (EPT/NON-RI) - SHIRE PLC
4th Dec 20189:11 amRNSForm 8.3 - Shire plc
4th Dec 20187:00 amGNWRule 2.9 Announcement
3rd Dec 20183:28 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
3rd Dec 20183:28 pmRNSForm 8.5 (EPT/NON-RI)
3rd Dec 20183:26 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
3rd Dec 20183:26 pmRNSForm 8.3 - Shire Plc
3rd Dec 20183:24 pmRNSForm 8.3 -Shire plc
3rd Dec 20183:24 pmRNSForm 8.3 - Shire plc
3rd Dec 20183:20 pmRNSForm 8.3 - Shire plc
3rd Dec 20183:20 pmGNWDavidson Kempner Capital Management LP : Form 8.3 - Shire PLC
3rd Dec 20183:20 pmBUSForm 8.3 - Shire PLC
3rd Dec 20183:01 pmRNSForm 8.3 - Shire Plc
3rd Dec 20183:00 pmBUSForm 8.3 - Shire PLC
3rd Dec 20182:45 pmEQSForm 8.3 - The Vanguard Group, Inc.: Shire plc
3rd Dec 20182:21 pmBUSForm 8.3 - SHIRE PLC
3rd Dec 20182:15 pmRNSForm 8.3 - [Shire Plc]
3rd Dec 20182:03 pmRNSForm 8.5 (EPT/NON-RI)
3rd Dec 20181:56 pmRNSForm 8.5 (EPT/RI) - Replacement of SHIRE
3rd Dec 20181:49 pmRNSForm 8.5 (EPT/RI) - Replacement of SHIRE PLC
3rd Dec 20181:43 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
3rd Dec 20181:40 pmRNSForm 8.3 - Shire plc
3rd Dec 201812:39 pmRNSForm 8.3 - Shire plc
3rd Dec 201812:34 pmRNSForm 8.3 - shire plc
3rd Dec 201812:34 pmRNSForm 8.3 - Takeda Pharmaceutical
3rd Dec 201812:00 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
3rd Dec 201811:57 amRNSForm 8.5 (EPT/RI)
3rd Dec 201811:39 amRNSForm 8.5 (EPT/NON-RI)- Shire Plc
3rd Dec 201811:26 amRNSForm 8.5 (EPT/NON-RI)
3rd Dec 201811:06 amRNSForm 8.5 - Shire Plc
3rd Dec 201810:51 amRNSForm 8.5 (EPT/RI) - SHIRE PLC
3rd Dec 201810:50 amRNSForm 8.5 (EPT/RI) - SHIRE PLC
3rd Dec 201810:48 amRNSForm 8.5 (EPT/RI) - SHIRE PLC
3rd Dec 201810:40 amRNSForm 8.5 (EPT/RI)- Shire plc
3rd Dec 201810:35 amRNSForm 8.5 (EPT/NON-RI) - SHIRE PLC
3rd Dec 201810:25 amRNSForm 8.5 (EPT/RI)
3rd Dec 20189:53 amRNSForm 8.3 - Shire Plc
3rd Dec 20189:25 amRNSForm 8.3 - Shire Plc
3rd Dec 20187:38 amRNSForm 8.3 - Shire plc
3rd Dec 20187:21 amRNSStatement regarding Loan Agreement
3rd Dec 20187:00 amRNSForm 8.3 - Shire Plc
3rd Dec 20187:00 amRNSForm 8.3 - Takeda Pharmaceutical Company Limited
3rd Dec 20187:00 amGNWTotal voting rights
3rd Dec 20187:00 amGNWRule 2.9 Announcement
30th Nov 20183:20 pmRNSForm 8.3 - Shire plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.